Recent Posts



  • happening across the industry, many companies pushing work to low cost countries like India. It's been tried before, many times, and has never panned out. always comes back to US, then a new set of leaders come in and say, hey, why don't we ship jobs to low cost countries to save money! and the cycle starts all over
    I'm all for saving a buck.so let's put India on the back burner. Makes more sense for Amgen to rid TO and SSF sites and exit California altogether. Other states are tax friendly and will bend over to attract Amgen.

anonymous
Jun 11, 2025 at 12:40 AM
  • We just can’t sell on the CCS team and are a mess because cards don’t buy it especially with class effect slogan from Lillly. And does any know who their medical support is? I call one and get passed to another one. Then another one. Jokers over there. Another guy wanting a kingdom and my whole team is confused on their line of support.
    stop your complaining do some research!!! Surpass-CVOT lasted the total length of the trial. It was not stopped early meaning it did not meet the number of events needed nor did it show any SHOW STOPPING early benefit like Sustain-6. You complainers have ZERO clue nor need to be a "CV Specialist."

anonymous
Jun 11, 2025 at 12:09 AM
  • I knew Tom in high school and I have to say I am really shocked reading all this. I was thinking about people who were dear to me back then and type in his name only to see all these Pharma threads pop up.

    I have no skin in the game other than to provide a different perspective to hopefully balance the other comments left about him in his older years. He was a dear friend of mine in the 80s and was one of the kindest people I knew. His family was wonderful and particularly his parents. He often got me through some very difficult times in high school and I recall he was incredibly intelligent. He was a top student at his school and was not awkward at all. In fact, he was quite the opposite. We met because he was so kind to stand up for me in a theater line. A class act.

    Anyway, I'm just shocked to read this terrible things about him when I can assure you, his core is nothing but genuine and caring.
    Mrs. Lyon may disagree.

anonymous
Jun 10, 2025 at 11:37 PM
  • Hey Bud, thanks for the tip see ya at Elsa’s this afternoon around 3. Cheers, Johnny Walker
    Got pulled over again last night from my Elsa’s Happy Hour with Johnny Walker, love those Long Island Ice Teas! Anyway my Mananager Jeff thought me this Placing a copper penny under your tongue does affect breathalyzer results in my favor. The Milwaukee cop said your under and sent me on the way.

anonymous
Jun 10, 2025 at 11:36 PM
  • I was given a range of $120 to $140k. Comp $47k at plan. I'm still confused on the description being speciality but the targets being allergy and immunology. Do the call on same targets with different drugs? The only drug I was told is Haegarda
    $140k base is more than the people here make that have been here the last 5 years. Very few peeps hit $47k (100%) at plan.
    There are some overlapping targets with Immunology (IVIG) vs Specialty (Haegarda and launching Gara). Specialty had Kcentra and that recently went generic (hospital based product). CSL really dropped the ball on contracting (absolute mess and totally clueless).
    CSL lied regarding the commission pay during the decline of the plan coverage - really wrong in so many ways. Absolutely no credibility and it was worse when the manager tried to convince the district that we didn't hear what was said at a national meeting. It was a shitty thing to do and leave it for the district managers to tell the reps that CSL reneged on commission and worse when the manager lied and defended the company.
    I expect a restructuring / downsizing after the launch - there is new big pharma management in play.

anonymous
Jun 10, 2025 at 11:19 PM